As we entered a new decade, BioWorld writers took the opportunity to review the highs and lows of the past 12 months and they concluded that 2019 was a great year for the sector – save for a few bumps in the road.

Investors warmed to biopharma company equities, particularly in the final quarter of the year, with the BioWorld Biopharmaceutical Index increasing 23% in value during this period, helping the group climb to a respectable 14% for the year after being underwater from April through to September.

The top 10 biopharma stock gainers and losers for the week.

Year-to-date money raised in public, private and other financings of biopharma companies.

Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018.

Venture capital and other private financings of private biopharma companies in December 2019.

Private placements and other private financings of public biopharma companies in December 2019.

Follow-ons completed by biopharma companies in December 2019.

Completed and pending initial public offerings by biopharma companies in December 2019.